期刊文献+

基于环糊精的纳米功能组装体的研究进展 被引量:4

Progress on Nano-assembly Based on Cyclodextrins
在线阅读 下载PDF
导出
摘要 通过分子自组装形成稳定和结构可控的材料是现在功能材料学、生物学的焦点,构筑纳米尺寸的功能性分子自组装体更是接近生命现象和过程的本质。基于环糊精的超分子组装以其选择性、可调控性和生物相容性等优势引起了广泛关注。本文就近十年来基于环糊精的纳米尺寸的功能组装体的研究进展进行简要综述,包括修饰环糊精的软连接自组装,环糊精轮烷、聚轮烷、纳米线、纳米管、纳米笼的设计、构筑及其更高级组装,以及环糊精与纳米粒子的分子组装和基于环糊精的分子机器。 It is very important to form a very stable, structure-controlled material by molecular assembly in the filelds of materials and life science. The fabrication of specific supramolecular systems in nano size with target biological functions is crucial important in revealing the nature and process of life. The self-assembly based on cych)dextrins becomes the focus recently due to the advantages of selectivity, regulating capability, biocompatibility and other interesting properties. The recent advances on various types of cyclodexrin assemblies are summarized, native and modified cyclodextrins, cyclodextrin rotaxanes and polyrotaxanes, cyclodextrin nanowire, nanotube, nanocage, and their secondary assembly, assembly of cyclodextrins and nanoparticles, and other high-order assembly based on cyclodextrins.
出处 《化学世界》 CAS CSCD 北大核心 2009年第3期178-181,185,共5页 Chemical World
基金 国家科技部863重点项目(No.2003AA2Z3267)
关键词 环糊精 超分子体系 自组装 cyclodextrins supramolecules self-assembly
  • 相关文献

参考文献29

二级参考文献56

共引文献29

同被引文献84

  • 1杨宗发,王苹.两亲性环糊精衍生物在毫微粒给药系统中的应用[J].中国药业,2006,15(19):60-61. 被引量:3
  • 2Amber V, Shailendra S, Swamlata S. Cyclodextrin based novel drug delivery systems. J Incl Phenom Macrocycl Chem, 2008, 62(1/2): 23-42.
  • 3Cirpanli Y, Bilensoy E, Lale Do,an A, et al. Comparative evaluation of polymeric and amphiphilic cyclodextrin nanoparticles for effective camptothecin delivery. Eur J Pharm Biopharm, 2009, 73(1):82-89.
  • 4Bilensoy E, Gurkaynak O, Ertan M, et al. Development of nonsurfactant cyclodextrin nanoparticles loaded with anticancer drug paclitaxel. J Pharm Sci, 2008, 97(4):1519-1529.
  • 5Geze A, Chau LT, Choisnard L, et al. Biodistribution of intravenously administered amphiphilic beta-cyclodextrin nanospheres. Int J Pharm, 2007, 344(1/2):135-142.
  • 6Defaye I, Garcia Fernandez JM, Ortiz Mellet C. Les cyclodextrines en pharmacie: perspectives pour le ciblage d'actifs therapeutiques et le controle d'interactions membranaires. Ann Pharm Fr, 2007, 65(1): 33-49.
  • 7Quaglia F, Ostacolo L, Mazzaglia A, et al. The intracellular effects of non-ionic arnphiphilic cyclodextrin nanoparticles in the delivery of anticancer drugs. Biomaterials, 2009, 30(3):374-382.
  • 8Schluep T, Gunawan P, Ma L, et al. Polymeric tubulysin-peptide nanoparticles with potent antitumor activity. Clin Cancer Res, 2009, 150):181-189.
  • 9Bilensoy E, Giirkaynak O, Do,an AL, et al. Safety and efficacy of amphiphilic beta-cyclodextrin nanoparticles for paclitaxel delivery. Int J Pharm, 2008, 347( 1/2):163-170.
  • 10Hwang J, Rodgers K, Oliver JC, et al. Alpha-methylprednisolone conjugated cyclodextrin polymer-based nanoparticles for rheumatoid arthritis therapy, lnt J Nanomedicine, 2008, 3(3):359-371.

引证文献4

二级引证文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部